Mucosal nanobody IgA as inhalable and affordable prophylactic and therapeutic treatment against SARS-CoV-2 and emerging variants

Anti-COVID antibody therapeutics have been developed but not widely used due to their high cost and escape of neutralization from the emerging variants. Here, we describe the development of VHH-IgA1.1, a nanobody IgA fusion molecule as an inhalable, affordable and less invasive prophylactic and ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Qi, Humphries, Fiachra, Girardin, Roxie C., Wallace, Aaron, Ejemel, Monir, Amcheslavsky, Alla, McMahon, Conor T., Schiller, Zachary A., Ma, Zepei, Cruz, John, Dupuis, Alan P., Payne, Anne F., Maryam, Arooma, Yilmaz, Nese Kurt, McDonough, Kathleen A., Pierce, Brian G., Schiffer, Celia A., Kruse, Andrew C., Klempner, Mark S., Cavacini, Lisa A., Fitzgerald, Katherine A., Wang, Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9512078/
https://www.ncbi.nlm.nih.gov/pubmed/36172366
http://dx.doi.org/10.3389/fimmu.2022.995412

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9512078/
https://www.ncbi.nlm.nih.gov/pubmed/36172366
http://dx.doi.org/10.3389/fimmu.2022.995412

Ejemplares similares